Mesoblast (MESO) Gains from Sales and Divestitures: 2015-2024
Historic Gains from Sales and Divestitures for Mesoblast (MESO) over the last 5 years, with Dec 2024 value amounting to $1,154.0 billion.
- Mesoblast's Gains from Sales and Divestitures rose 13.66% to $1,154.0 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1,154.0 billion, marking a year-over-year increase of 13.66%. This contributed to the annual value of $1,141.8 billion for FY2024, which is 40.23% up from last year.
- Latest data reveals that Mesoblast reported Gains from Sales and Divestitures of $1,154.0 billion as of Q4 2024, which was up 1.07% from $1,141.8 billion recorded in Q2 2024.
- Over the past 5 years, Mesoblast's Gains from Sales and Divestitures peaked at $1,154.0 billion during Q4 2024, and registered a low of $587.6 million during Q4 2020.
- For the 3-year period, Mesoblast's Gains from Sales and Divestitures averaged around $694.7 billion, with its median value being $737.1 billion (2022).
- In the last 5 years, Mesoblast's Gains from Sales and Divestitures slumped by 99.89% in 2020 and then skyrocketed by 63,249.10% in 2022.
- Mesoblast's Gains from Sales and Divestitures (Quarterly) stood at $587.6 million in 2020, then spiked by 98.03% to $1.2 billion in 2021, then skyrocketed by 63,249.10% to $737.1 billion in 2022, then soared by 37.74% to $1,015.3 billion in 2023, then increased by 13.66% to $1,154.0 billion in 2024.
- Its last three reported values are $1,154.0 billion in Q4 2024, $1,141.8 billion for Q2 2024, and $1,015.3 billion during Q4 2023.